| 形态 | Liquid |
|---|---|
| 宿主种属 | Human |
| 克隆性 | Monoclonal |
| 抗体亚型 | IgG4-kappa |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 浓度 | 1mg/ml |
| 内毒素水平 | Please contact the lab for this information. |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 种属反应性 | Human |
| 靶标 | Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 表达系统 | Mammalian Cells |
| 登录号 | Q07011 |
| 背景信息 | Urelumab is a fully humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer-Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. In December 2008, enrolment was stopped for all urelumab studies following the occurrence of two hepatotoxicity-related deaths. Several years later, the clinical study on Urelumab was restarted. At present, the approval of the monoclonal antibody has not been disclosed in the relevant drug approval agency. • Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB., PMID:9045669 • ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages., PMID:7849293 • CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes., PMID:10607752 • CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling., PMID:9498794 • A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis., PMID:9485208 • CD137-induced apoptosis is independent of CD95., PMID:10469232 • CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils., PMID:11093162 • Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2., PMID:13130507 • Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation., PMID:10873573 • CD137 expression in tumor vessel walls. High correlation with malignant tumors., PMID:11293902 |
| 别名 | 2639688-77-8 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
| 产品名称 | 点击数 |
|---|---|
| 过氧化物酶(HRP)标莱克多巴胺单克隆抗体 | 5889 |
| 过氧化物酶(HRP)标沙丁胺醇单克隆抗体 | 5854 |
| 呋喃唑酮代谢物(2-NPAOZ)单抗 | 6327 |
| 环丙沙星(CPFX)单抗 | 5765 |
| 氟喹诺酮类单抗 | 5868 |
| 恩诺沙星单抗 | 5766 |
| 环丙沙星|恩诺沙星|诺氟沙星三合一单抗 | 5834 |
| 睾酮单抗 | 5740 |
| 过氧化物酶(HRP)标睾酮单克隆抗体 | 5672 |
| 过氧化物酶(HRP)标雌三醇单克隆抗体 | 5894 |
| 过氧化物酶(HRP)标记甲基睾酮单克隆抗体 | 6110 |
| 黄曲霉毒素抗体(黄曲霉毒素B1,黄曲霉毒素总量单克隆抗体) | 5735 |
| 苏丹红1号单抗 | 6015 |
| 呋喃西林代谢物(2-NPSEM)单抗(40F11细胞株) | 5597 |
| 小鼠单克隆抗体Ig类/亚类鉴定ELISA试剂盒 | 6552 |
| 小鼠单克隆抗体Ig类/亚类/亚型鉴定ELISA试剂盒 | 6771 |
| 小鼠单克隆抗体Ig类/亚类/亚型鉴定酶标二抗即用套装 | 6694 |
| HRP标记小鼠单抗专用稀释液 | 6761 |
| 小鼠单抗腹水制备专用佐剂套装 | 6768 |
| 新冠病毒S蛋白中和抗体ELISA检测试剂盒 | 6557 |